Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22851377 | 0.94 | POLB (0.38) | ALDH1A1KDM4EPOLB | |
| SCHEMBL20463277 | 0.91 | ODC1 (0.39) | ALDH1A1KDM4EPOLBMEN1LMNA | |
| SCHEMBL18295131 | 0.89 | ODC1 (0.37) | ALDH1A1KDM4EPOLBMEN1LMNA | |
| SCHEMBL17552875 | 0.89 | ALDH1A1 (0.39) | ALDH1A1KDM4EPOLBMEN1LMNA | |
| SCHEMBL22547111 | 0.86 | ALDH1A1 (0.36) | ALDH1A1KDM4EPOLBMEN1LMNA | |
| SCHEMBL8056764 | 0.86 | KDM4E (0.36) | ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL14176494 | 0.86 | KDM4E (0.42) | ALDH1A1KDM4EPOLBMEN1LMNA | |
| SCHEMBL14929069 | 0.86 | KDM4E (0.35) | ALDH1A1KDM4EPOLBMEN1KMT2A | |
| SCHEMBL18792783 | 0.84 | KDM4E (0.39) | ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL8063331 | 0.84 | KDM4E (0.39) | ALDH1A1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-11584748-B2 | Spirocyclic compounds | C4 THERAPEUTICS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20230019060-A1 | HETEROCYCLIC COMPOUNDS FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-11524949-B2 | Degraders and Degrons for targeted protein degradation | C4 THERAPEUTICS, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-11242323-B2 | Inhibition of OLIG2 activity | Curtana Pharmaceuticals, Inc. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20210253535-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2021-08-19 | — | — | US | disclosed |
| US-20210032245-A1 | SPIROCYCLIC COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2021-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230019060-A1 | HETEROCYCLIC COMPOUNDS FOR MEDICAL TREATMENT | CRBN, MDM2, RBX1 | ALDH1A1 2742/4885KDM4E 1086/4885POLB 2379/4885 |
| US-20210253535-A1 | INHIBITION OF OLIG2 ACTIVITY | GLI2, ING2, GMFG | ALDH1A1 1478/4885KDM4E 2547/4885POLB 1413/4885 |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | STUB1, MDM2, USP30 | ALDH1A1 3735/4885KDM4E 1975/4885POLB 2996/4885 |
| US-20210032245-A1 | SPIROCYCLIC COMPOUNDS | CRBN, RBX1, XIAP | ALDH1A1 2000/4885KDM4E 1861/4885POLB 3114/4885 |
| US-11242323-B2 | Inhibition of OLIG2 activity | POU2F2, ING2, PAX2 | ALDH1A1 1801/4885KDM4E 2188/4885POLB 935/4885 |
| US-11524949-B2 | Degraders and Degrons for targeted protein degradation | STUB1, MDM2, USP30 | ALDH1A1 3735/4885KDM4E 1975/4885POLB 2996/4885 |
| US-11584748-B2 | Spirocyclic compounds | CRBN, RBX1, XIAP | ALDH1A1 2000/4885KDM4E 1861/4885POLB 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.